159 related articles for article (PubMed ID: 10935487)
1. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Abramovitch R; Dafni H; Neeman M; Nagler A; Pines M
Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487
[TBL] [Abstract][Full Text] [Related]
2. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Pinthus JH; Sheffer Y; Nagler A; Fridman E; Mor Y; Genina O; Pines M
J Urol; 2005 Oct; 174(4 Pt 2):1527-31. PubMed ID: 16148645
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Nagler A; Genina O; Lavelin I; Ohana M; Pines M
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
[TBL] [Abstract][Full Text] [Related]
7. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
9. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
10. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
[TBL] [Abstract][Full Text] [Related]
11. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
Yee KO; Connolly CM; Pines M; Lawler J
Cancer Biol Ther; 2006 Feb; 5(2):218-24. PubMed ID: 16418571
[TBL] [Abstract][Full Text] [Related]
13. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
[TBL] [Abstract][Full Text] [Related]
15. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study.
Abramovitch R; Itzik A; Harel H; Nagler A; Vlodavsky I; Siegal T
Neoplasia; 2004; 6(5):480-9. PubMed ID: 15548356
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
Elkin M; Miao HQ; Nagler A; Aingorn E; Reich R; Hemo I; Dou HL; Pines M; Vlodavsky I
FASEB J; 2000 Dec; 14(15):2477-85. PubMed ID: 11099465
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
18. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone.
Nagler A; Katz A; Aingorn H; Miao HQ; Condiotti R; Genina O; Pines M; Vlodavsky I
Kidney Int; 1997 Dec; 52(6):1561-9. PubMed ID: 9407501
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
